Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of FG-4592 vs Epoetin Alfa for Anemia in Incident Dialysis Patients
2013-002753-30Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anemia due to end-stage renal disease and secondary anemia (2 arms), sponsored by FibroGen. Primary endpoint: Hemoglobin response within first 24 weeks. Started Nov 2013; status: terminated.
02
Drugs
roxadustat
03
Conditions
anemia due to end-stage renal diseasesecondary anemia
Beyond the preview
Go deeper on 2013-002753-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002753-30.